Category: Patients
May 6, 2019
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More
May 1, 2019
Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...
Read More
December 21, 2018
New MAP Feature: Treatment Center Comparator
Finding the best amyloidosis care is not easy, so in 2017 ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. Now MAP can do even more. (more…)
Read More
- Categories
- Archives
- February 2021 (1)
- January 2021 (2)
- December 2020 (1)
- November 2020 (2)
- October 2020 (1)
- September 2020 (1)
- July 2020 (1)
- February 2020 (2)
- January 2020 (2)
- December 2019 (1)
- November 2019 (3)
- October 2019 (1)
- September 2019 (3)
- August 2019 (1)
- June 2019 (1)
- May 2019 (2)
- March 2019 (2)
- February 2019 (1)
- January 2019 (1)
- December 2018 (3)
- October 2018 (2)
- September 2018 (1)
- August 2018 (2)
- July 2018 (2)
- April 2018 (3)
- March 2018 (2)
- February 2018 (3)
- January 2018 (2)
- December 2017 (4)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- April 2017 (1)
- February 2017 (1)
- December 2016 (2)
- October 2016 (2)
- September 2016 (1)
- July 2016 (3)
- June 2016 (4)
- May 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (2)
- December 2015 (1)
- November 2015 (2)
- October 2015 (1)
- September 2015 (1) More
